SCHEMBL4382860

SCHEMBL4382860

C=CCC(O)Cc1c(CC)c(OCOC)cc(OCOC)c1-c1ccccc1

nearest known ligand 0.34

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.34
CAPN1 P07384 1/20 0.30
GCGR P47871 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4380830 0.89 EGFR (0.33) EGFR
SCHEMBL4384285 0.87 EGFR (0.35) EGFRCAPN1GCGR
SCHEMBL4384944 0.86 EGFR (0.39) EGFRCAPN1GCGR
SCHEMBL4384312 0.83 EGFR (0.39) EGFRCAPN1GCGR
SCHEMBL4381681 0.83 EGFR (0.36) EGFR
SCHEMBL4378145 0.81 EGFR (0.40) EGFRCAPN1GCGR
SCHEMBL4383919 0.80 EGFR (0.34) EGFRCAPN1GCGR
SCHEMBL4381841 0.77 EGFR (0.32) EGFR
SCHEMBL4381984 0.77 EGFR (0.41) EGFRGCGR
SCHEMBL4386776 0.76 EGFR (0.43) EGFRCAPN1GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538241-B2 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-05-26 US disclosed
US-20070155813-A1 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-07-05 US disclosed
EP-1704856-A1 HSP90 FAMILY PROTEIN INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-09-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155813-A1 Hsp90 family protein inhibitors HSP90AB1, HEATR1, HSP90AB2P EGFR 624/4885CAPN1 1225/4885GCGR 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.